Katalin Karikó

Katalin Karikó, born on January seventeenth, nineteen fifty-five, is a distinguished Hungarian-American biochemist renowned for her pioneering work in ribonucleic acid (RNA)-mediated mechanisms. Her groundbreaking research, particularly in in vitro-transcribed messenger RNA (mRNA), has laid the essential scientific groundwork for mRNA vaccines, a feat achieved despite facing significant skepticism and obstacles within the scientific community.

In recognition of her monumental contributions, Karikó was awarded the Nobel Prize in Physiology or Medicine in two thousand twenty-three, sharing this honor with American immunologist Drew Weissman. Their collaborative efforts led to the co-discovery of nucleoside modifications that effectively suppress the immunogenicity of RNA, further advancing the therapeutic applications of mRNA.

Karikó's professional journey includes co-founding RNARx, where she served as CEO from two thousand six to two thousand thirteen. Following this, she joined BioNTech RNA Pharmaceuticals, initially as vice president and later promoted to senior vice president in two thousand nineteen. In two thousand twenty-two, she transitioned from BioNTech to focus more on her research endeavors. Her academic contributions have also been recognized with an honorary doctorate from the University of Szeged in Hungary, where she has taken on a professorship.

Despite her achievements, Karikó faced challenges during her tenure at the University of Pennsylvania, where she was underfunded and demoted in nineteen ninety-five, ultimately never receiving tenure. Nevertheless, her innovative work has been instrumental in the development of mRNA-based technologies, which have been licensed by BioNTech and Moderna for their COVID-19 vaccines, significantly aiding in the global fight against the SARS-CoV-2 virus.

In addition to the Nobel Prize, Karikó and Weissman have garnered numerous accolades, including the Lasker–DeBakey Clinical Medical Research Award, Time Magazine's Hero of the Year in two thousand twenty-one, and the Tang Prize Award in Biopharmaceutical Science in two thousand twenty-two. Their contributions have not only advanced scientific understanding but have also played a crucial role in addressing the COVID-19 pandemic.